ARCHIVES

FDA Approves Gemzar For Ovarian Cancer, Contradicting ODAC Recommendation; Continues Agency Trend to Recognize Progression-Free Survival As An Endpoint.

This article is from The Cancer Letter archive.

Vol. 32 No. 28 | July 21, 2006

Download PDF Visit The Full Archive

Related Articles

In Brief: Senate Committee Cuts House Amount For NCI; NCI Staff Faces Up to 22 Days Unpaid Leave

September 21, 1990

Elm {15 for 17} Has Some Advice For Would Be CCOPs

July 18, 1986

Kansas Gov. Sebelius Nominated For HHS

March 6, 2009

Officals: “Separations” in Normal Range as Critics Claim Brain Drain in the Clinic

January 17, 2014

Cancer Advocacy: Jay Hedlund Resigns As NPCC President

May 14, 1999

White House Agrees To Pay Raise For NCI, NIH, NHLI Chiefs

February 27, 1976